|1.||Sebti, Said: 2 articles (09/2015 - 11/2013)|
|2.||Husain, Kazim: 1 article (09/2015)|
|3.||Kim, Richard: 1 article (09/2015)|
|4.||Yamauchi, Teruo: 1 article (09/2015)|
|5.||Malafa, Mokenge: 1 article (09/2015)|
|6.||Malik, Asifa: 1 article (11/2013)|
|7.||Lancet, Jeffrey E: 1 article (11/2013)|
|8.||Ravandi, Farhad: 1 article (11/2013)|
|9.||Kantarjian, Hagop M: 1 article (11/2013)|
|10.||Sampath, Deepa: 1 article (11/2013)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
01/01/1986 - "These data suggest that TCN-P is most likely to be clinically effective against ovarian cancer, and may be non-cross-resistant with several standard agents, if administered by continuous infusion. "
01/01/1986 - "TCN-P reduced both colony number and volume in clonogenic assays employing human ovarian cancer cell lines. "
01/01/1986 - "Tricyclic nucleoside 5'-phosphate (TCN-P) was evaluated in two models of human ovarian cancer. "
01/01/1986 - "Intermittent bolus TCN-P (100 mg/kg/d X 5) was ineffective in an in vivo xenograft model of human ovarian cancer. "
12/01/2011 - "In this phase I study triciribine phosphate monohydrate (TCN-PM) was administered to subjects whose tumors displayed evidence of increased AKT phosphorylation (p-AKT) as measured by immunohistochemical analysis (IHC). "
12/01/2011 - "Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT."
11/01/2010 - "Thus, the results of our studies indicate that TCN-P binds to the PH domain of Akt and blocks its recruitment to the membrane, and that the subsequent inhibition of Akt phosphorylation contributes to TCN-P antiproliferative and proapoptotic activities, suggesting that this drug may be beneficial to patients whose tumors express persistently phosphorylated Akt."
01/11/1985 - "The assay was used to determine plasma and tissue concentrations of TCN-P and TCN after administration of TCN-P to cancer patients in a Phase I clinical study."
06/01/2003 - "The results suggest ADK expression may be useful for stratifying TCN-P-responsive vs. non-responsive tumors. "
|3.||Hematologic Neoplasms (Hematological Malignancy)
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|1.||K 76 carboxylic acid
|1.||Heterologous Transplantation (Xenotransplantation)